GGrantIndex
← Leaderboards

Denise R Aberle

University Of California Los Angeles

$7,414,266
Attributed
$24,258,930
Total exposure
8
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.5M · FY201525
$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$24,258,930 · 8

By mechanism

U01$18,048,652 · 3
R01$5,433,038 · 2
P01$777,240 · 2
P50$0 · 1

Top collaborators

Most similar at University Of California Los Angeles

Same institution · by research overlap

Others in their field

Top investigators on “Image

Research focus

ImageMalignant NeoplasmsScreeningMalignant Neoplasm Of LungNoduleProspectiveBaseMolecularLungBiological MarkersX-Ray Computed TomographyLung Cancer ScreeningDiagnosticBenignMalignant - DescriptorLung NoduleSmokerEvaluationCohortCancer DiagnosisMortalityCharacteristicsPredictive ModelingCancer Detection

Grant awards (39)

EFIRM Liquid Biopsy Research Laboratory: Early Lung Cancer Assessment$2,745,735
U01 · FY2025 · CA
EFIRM Liquid Biopsy Research Laboratory: Early Lung Cancer Assessment$878,436
U01 · FY2024 · CA
EFIRM Liquid Biopsy Research Laboratory: Early Lung Cancer Assessment$932,148
U01 · FY2023 · CA
Individually-tailored clinical decision support for management of indeterminate pulmonary nodules$447,621
R01 · FY2023 · CA
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer$647,157
U01 · FY2022 · CA
Individually-tailored clinical decision support for management of indeterminate pulmonary nodules$455,471
R01 · FY2022 · CA
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer$670,270
U01 · FY2021 · CA
Individually-tailored clinical decision support for management of indeterminate pulmonary nodules$464,766
R01 · FY2021 · CA
The Boston University-UCLA Lung Cancer Biomarker Development Lab$216,625
U01 · FY2021 · CA
Molecular and Imaging Biomarkers for Early Lung Cancer Detection in the Setting of Indeterminate Pulmonary Nodules$181,082
R01 · FY2021 · CA
Integrated Molecular, Cellular, and Imaging Characterization of NLST detected lung cancer$156,000
U01 · FY2021 · CA
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer$669,593
U01 · FY2020 · CA
Molecular and Imaging Biomarkers for Early Lung Cancer Detection in the Setting of Indeterminate Pulmonary Nodules$627,805
R01 · FY2020 · CA
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer$624,935
U01 · FY2020 · CA
Individually-tailored clinical decision support for management of indeterminate pulmonary nodules$456,756
R01 · FY2020 · CA
The Boston University-UCLA Lung Cancer Biomarker Development Lab$417,771
U01 · FY2020 · CA
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer$798,798
U01 · FY2019 · CA
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer$652,690
U01 · FY2019 · CA
The Boston University-UCLA Lung Cancer Biomarker Development Lab$516,250
U01 · FY2019 · CA
Individually-tailored clinical decision support for management of indeterminate pulmonary nodules$464,766
R01 · FY2019 · CA
Molecular and Imaging Biomarkers for Early Lung Cancer Detection in the Setting of Indeterminate Pulmonary Nodules$409,210
R01 · FY2019 · CA
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer$1,218,395
U01 · FY2018 · CA
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer$685,403
U01 · FY2018 · CA
Molecular and Imaging Biomarkers for Early Lung Cancer Detection in the Setting of Indeterminate Pulmonary Nodules$621,526
R01 · FY2018 · CA
The Boston University-UCLA Lung Cancer Biomarker Development Lab$518,499
U01 · FY2018 · CA
The Boston University-UCLA Lung Cancer Biomarker Development Lab$860,456
U01 · FY2017 · CA
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer$764,788
U01 · FY2017 · CA
Molecular and Imaging Biomarkers for Early Lung Cancer Detection in the Setting of Indeterminate Pulmonary Nodules$627,525
R01 · FY2017 · CA
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer$456,656
U01 · FY2017 · CA
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer$2,239,851
U01 · FY2016 · CA
Molecular and Imaging Biomarkers for Early Lung Cancer Detection in the Setting of Indeterminate Pulmonary Nodules$676,510
R01 · FY2016 · CA
The Boston University-UCLA Lung Cancer Biomarker Development Lab$565,669
U01 · FY2016 · CA
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer$812,527
U01 · FY2015 · CA
MULTIMEDIA ARCHITECTURE FOR THORACIC DISEASES$152,750
P01 · FY2002 · EB
Combined CT-PET /in vivo lung nodule characterization$0
P50 · FY2002 · CA
MULTIMEDIA ARCHITECTURE FOR THORACIC DISEASES$152,750
P01 · FY2001 · CA
Combined CT-PET /in vivo lung nodule characterization$0
P50 · FY2001 · CA
PACS FOR THORACIC IMAGING$318,990
P01 · FY2000 · CA
MULTIMEDIA ARCHITECTURE FOR THORACIC DISEASES$152,750
P01 · FY2000 · CA